PureTech’s Celea Posts Positive Phase 2b IPF Data, Paving Way for Phase 3 Deupirfenidone Trial

An update from PureTech Health ( (GB:PRTC) ) is now available.

PureTech Health, through its wholly owned Founded Entity Celea Therapeutics, is advancing deupirfenidone, a deuterated form of the approved IPF drug pirfenidone, as a next-generation antifibrotic therapy. The company’s model centers on spinning out and funding specialized entities to progress high-potential biotherapeutics programs in a capital-efficient way.

PureTech announced that the Phase 2b ELEVATE IPF trial of deupirfenidone has been published in The American Journal of Respiratory and Critical Care Medicine, showing that 825 mg TID monotherapy significantly slowed lung function decline versus placebo over 26 weeks and approached the decline expected in healthy aging. The trial, which uniquely included both a placebo and pirfenidone active comparator arm, met primary and key secondary endpoints, demonstrated a delay in disease progression, showed higher drug exposure without compromising tolerability, and underpins a Phase 3 head-to-head SURPASS-IPF trial against pirfenidone that Celea plans to initiate in the first half of 2026.

The most recent analyst rating on (GB:PRTC) stock is a Hold with a £139.00 price target. To see the full list of analyst forecasts on PureTech Health stock, see the GB:PRTC Stock Forecast page.

Spark’s Take on PRTC Stock

According to Spark, TipRanks’ AI Analyst, PRTC is a Neutral.

PureTech Health’s overall score reflects a balance of strong liquidity and promising clinical developments against challenges in profitability and technical weakness. The company’s strategic initiatives and recent positive trial results provide a cautiously optimistic outlook, but operational risks and funding uncertainties remain significant factors.

To see Spark’s full report on PRTC stock, click here.

More about PureTech Health

PureTech Health is a hub-and-spoke biotherapeutics company that creates and develops innovative medicines through wholly owned “Founded Entities” such as Celea Therapeutics. Celea focuses on serious respiratory diseases, with lead candidate deupirfenidone (LYT-100) positioned as a potential next-generation standard of care for idiopathic pulmonary fibrosis and other fibrotic lung conditions.

Average Trading Volume: 462,244

Technical Sentiment Signal: Strong Sell

Current Market Cap: £267.8M

For detailed information about PRTC stock, go to TipRanks’ Stock Analysis page.